Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference GlobeNewswire - Wed May 28, 7:00AM CDT

CMPX : 2.70 (-5.26%)
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update GlobeNewswire - Thu May 8, 7:00AM CDT

CMPX : 2.70 (-5.26%)
Compass Therapeutics to Participate in Upcoming May Investor Events GlobeNewswire - Tue May 6, 7:00AM CDT

CMPX : 2.70 (-5.26%)
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire - Mon Apr 28, 7:00AM CDT

CMPX : 2.70 (-5.26%)
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer GlobeNewswire - Mon Apr 21, 7:00AM CDT

CMPX : 2.70 (-5.26%)
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum GlobeNewswire - Wed Apr 2, 3:05PM CDT

CMPX : 2.70 (-5.26%)
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer GlobeNewswire - Tue Apr 1, 6:00AM CDT

CMPX : 2.70 (-5.26%)
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer GlobeNewswire - Mon Mar 31, 3:05PM CDT

CMPX : 2.70 (-5.26%)
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update GlobeNewswire - Thu Feb 27, 7:00AM CST

CMPX : 2.70 (-5.26%)
Author
Top 3 High-Momentum Companies Analysts Are Still Bullish On MarketBeat - Tue Feb 4, 6:00AM CST

Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.

AVAV : 263.80 (+11.04%)
AMPX : 6.44 (-0.92%)
CMPX : 2.70 (-5.26%)
ALLT : 9.75 (-5.89%)

Barchart Exclusives

Gold's Bull Run: Seasonal Strength Meets Conflicting COT Report—Are You In? Barchart - Sat Jul 12, 2:47PM CDT
Gold's all-time high $3,509.9! Central banks bought big, but the COT report waves a red flag. Seasonal gains await—Market players, read or regret! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot